Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy

What is the purpose of this trial?

This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 /PD-L1 based immunotherapy.

Approximately 140 patients are anticipated to be enrolled across approximately 50 sites from North America and Europe.


Participation Guidelines

Ages: 18 years and older

Gender: Both


Immunomedics, Inc.

Start Date: 11/14/2018

End Date: 12/31/2021

Last Updated: 12/06/2018

Study HIC#: 2000023211

Get Involved

For more information about this study, contact:
Matthew Piscatelli
+1 203-737-8367
matthew.piscatelli@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image